ITMI960458A0 - - Google Patents

Info

Publication number
ITMI960458A0
ITMI960458A0 ITMI960458A ITMI960458A ITMI960458A0 IT MI960458 A0 ITMI960458 A0 IT MI960458A0 IT MI960458 A ITMI960458 A IT MI960458A IT MI960458 A ITMI960458 A IT MI960458A IT MI960458 A0 ITMI960458 A0 IT MI960458A0
Authority
IT
Italy
Application number
ITMI960458A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ITMI960458A0 publication Critical patent/ITMI960458A0/it
Priority to IT96MI000458A priority Critical patent/IT1283218B1/it
Priority to EP97906153A priority patent/EP0885202A1/en
Priority to AU20946/97A priority patent/AU2094697A/en
Priority to PCT/EP1997/001048 priority patent/WO1997032862A1/en
Priority to EP01118591A priority patent/EP1151997A1/en
Priority to JP9531441A priority patent/JP2000506152A/ja
Priority to ZA9701995A priority patent/ZA971995B/xx
Publication of ITMI960458A1 publication Critical patent/ITMI960458A1/it
Application granted granted Critical
Publication of IT1283218B1 publication Critical patent/IT1283218B1/it
Priority to US09/659,593 priority patent/US6719958B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/76—Metal complexes of amino carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IT96MI000458A 1996-03-08 1996-03-08 Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi IT1283218B1 (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IT96MI000458A IT1283218B1 (it) 1996-03-08 1996-03-08 Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
EP01118591A EP1151997A1 (en) 1996-03-08 1997-03-03 Polychelants, their complexes with metal ions, their preparation and their uses
AU20946/97A AU2094697A (en) 1996-03-08 1997-03-03 Polychelants, their complexes with metal ions, their preparation and their uses
PCT/EP1997/001048 WO1997032862A1 (en) 1996-03-08 1997-03-03 Polychelants, their complexes with metal ions, their preparation and their uses
EP97906153A EP0885202A1 (en) 1996-03-08 1997-03-03 Polychelants, their complexes with metal ions, their preparation and their uses
JP9531441A JP2000506152A (ja) 1996-03-08 1997-03-03 ポリキラント類、金属イオン類とのそれらの錯体類、それらの製造法及びそれらの用途
ZA9701995A ZA971995B (en) 1996-03-08 1997-03-07 Polychelants, their complexes with metal ions, their preparation and their uses.
US09/659,593 US6719958B1 (en) 1996-03-08 2000-09-11 Polychelants, their complexes with metal ions, their preparation and their uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI000458A IT1283218B1 (it) 1996-03-08 1996-03-08 Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi

Publications (3)

Publication Number Publication Date
ITMI960458A0 true ITMI960458A0 (it) 1996-03-08
ITMI960458A1 ITMI960458A1 (it) 1997-09-08
IT1283218B1 IT1283218B1 (it) 1998-04-16

Family

ID=11373558

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96MI000458A IT1283218B1 (it) 1996-03-08 1996-03-08 Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi

Country Status (7)

Country Link
US (1) US6719958B1 (it)
EP (2) EP1151997A1 (it)
JP (1) JP2000506152A (it)
AU (1) AU2094697A (it)
IT (1) IT1283218B1 (it)
WO (1) WO1997032862A1 (it)
ZA (1) ZA971995B (it)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770261B2 (en) 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
IT1291623B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
IT1291624B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
US6713046B1 (en) 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
CA2309749A1 (en) 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
CA2356532A1 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
HUP0202635A3 (en) 1999-07-29 2006-03-28 Epix Medical Inc Cambridge Targeting multimeric imaging agents through multilocus binding
IT1317862B1 (it) * 2000-02-29 2003-07-15 Bracco Spa Coniugati di acidi biliari con chelati complessi di ioni metallici eloro uso.
US6565828B2 (en) 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
US6656450B2 (en) 2000-07-17 2003-12-02 California Institute Of Technology, Inc. Macrocyclic magnetic resonance imaging contrast agents
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US6517814B2 (en) 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
HUP0400027A3 (en) 2001-02-23 2006-01-30 Bristol Myers Squibb Pharma Co Labeled macrophage scavenger receptor antagonosts for imaging atherosclerosis and vulnerable plaque
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US7192586B2 (en) 2001-09-20 2007-03-20 Cornell Research Foundation, Inc. Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
EP1369134A1 (en) 2002-06-05 2003-12-10 Bracco Imaging S.p.A. New agents for magnetic imaging method
ES2314272T3 (es) 2003-01-10 2009-03-16 Millennium Pharmaceuticals, Inc. Metodos para el diagnostico y el tratamiento del cancer.
FR2857967B1 (fr) * 2003-07-25 2015-04-24 Centre Nat Rech Scient Complexes de lanthanide, leur preparation et leurs utilisations
JP2008508333A (ja) * 2004-08-05 2008-03-21 ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン 標的分子の改変および組織化のための多価キレーター
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
FR2883562B1 (fr) 2005-03-24 2009-02-27 Guerbet Sa Chelates lipophiles et leur utilisation en imagerie
JP5064761B2 (ja) 2005-12-21 2012-10-31 富士フイルム株式会社 ジエチレントリアミン型金属キレート構造を有する高級脂肪酸トリエステル及びアミド誘導体
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
EP2338874A1 (en) * 2009-12-16 2011-06-29 Bracco Imaging S.p.A Process for the preparation of chelated compounds
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US10610608B2 (en) 2013-08-01 2020-04-07 Rochester Institute Of Technology Modular imaging agents containing amino acids and peptides
ES2729841T3 (es) * 2013-09-18 2019-11-06 Aura Biosciences Inc Conjugados de partículas similares a virus para tratar tumores
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
CA3003728A1 (en) 2015-10-30 2017-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Targeted cancer therapy
CN110139644B (zh) * 2016-09-07 2023-05-23 坦普尔大学 用于治疗胰岛素抵抗的组合物和方法
CN110035996B (zh) * 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
CN112088006A (zh) * 2018-03-07 2020-12-15 坦普尔大学 用于治疗胰岛素抵抗的组合物和方法
JP6848015B2 (ja) 2018-07-17 2021-03-24 コリア アトミック エナジー リサーチ インスティテュートＫｏｒｅａ Ａｔｏｍｉｃ Ｅｎｅｒｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 放射性元素の標識方法、放射性標識化合物、及びそれを含む放射性元素標識キット
KR102230657B1 (ko) * 2018-07-17 2021-03-23 한국원자력연구원 방사성 원소의 표지방법, 방사성 표지화합물 및 이를 포함하는 방사성 원소 표지 키트
PE20211471A1 (es) 2018-11-23 2021-08-05 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos
EP4059925A1 (en) 2021-03-15 2022-09-21 Bayer Aktiengesellschaft New contrast agent for use in magnetic resonance imaging
EP4335840A1 (en) 2022-09-09 2024-03-13 Bayer Aktiengesellschaft New contrast agents for use in diagnostic imaging
EP4335462A1 (en) 2022-09-09 2024-03-13 Bayer AG Contrast agents for use in diagnostic computed tomography imaging

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596992B1 (fr) * 1986-04-11 1988-12-16 Guerbet Sa Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
EP0661279B1 (fr) * 1993-12-30 2001-03-07 Guerbet Ligands polyaminés, complexes métalliques, procédé de préparation, applications diagnostiques et thérapeutiques
JP3878208B2 (ja) * 1994-04-08 2007-02-07 ブラッコ インターナショナル ベスローテン フェンノートシャップ 芳香族アミド化合物およびそれらのキレート

Also Published As

Publication number Publication date
IT1283218B1 (it) 1998-04-16
ZA971995B (en) 1998-06-23
AU2094697A (en) 1997-09-22
ITMI960458A1 (it) 1997-09-08
EP0885202A1 (en) 1998-12-23
WO1997032862A1 (en) 1997-09-12
JP2000506152A (ja) 2000-05-23
EP1151997A1 (en) 2001-11-07
US6719958B1 (en) 2004-04-13

Similar Documents

Publication Publication Date Title
AR026661A2 (it)
BRPI9713914B8 (it)
ITMI960458A0 (it)
IN191574B (it)
BR7600721U (it)
BR7601346U (it)
BR9603859A (it)
CN3044348S (it)
CN3045880S (it)
CN3040024S (it)
CN3040367S (it)
CN3040543S (it)
CN3040805S (it)
CN3041207S (it)
CN3041374S (it)
CN3041383S (it)
CN3042289S (it)
CN3042589S (it)
CN3043305S (it)
CN3044168S (it)
CN3044346S (it)
CN3044347S (it)
CN3046296S (it)
CN3044349S (it)
CN3045208S (it)

Legal Events

Date Code Title Description
0001 Granted